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To the Editor:
I read the review article by Dr Chen [1] with grave con-
cern. First, in the section of “Difference between obser-
vational studies and RCTs on cardiovascular effects”,
under the title “Observational trials of HT”, “Meta-
analysis of epidemiological data from several observa-
tional trials [3–10]…” was quoted. Epidemiologic
studies are traditionally classified as either observa-
tional or experimental. In an observational study, the
investigator measures but does not intervene. Therefore,
observational studies should better not be quoted as
observational trials. Epidemiologic studies are prima-
rily descriptive or analytic. Analytic studies may be
subdivided into nonexperimental (observational) and
experimental studies. Nonexperimental analytic stud-
ies include cohort and case-control studies, and take
advantage of “natural experiments” in which individu-
als do not involve in any kind of trial. Experimental
studies include clinical trials. Randomization of the
treatment assignment is the cornerstone of a good
clinical trial. Field and community intervention trials
are considered as experimental studies [2]. The major
difference between clinical trials and observational
studies is that, in clinical trials, the investigators
manipulate the administration of a new interven-
tion and measure the effect of that manipulation,
whereas observational studies only observe associations
(correlations) between the treatments experienced by 
participants and their health status or diseases. These
are fundamental distinctions in evidence-based medi-
cine [3]. For example, level I evidence is the evidence
obtained from at least one properly designed ran-
domized controlled trial; by the way, RCTs are now
considered the “gold standard” in the field of clinical
research.
Second, I found that all the reference numbers
quoted in both Table 1 and Table 2 are incorrect.
Please amend.
Horng-Jyh Tsai, MD, FACOG
Department of Obstetrics and Gynecology
Chung-Shan Medical University Hospital
110, Section 1, Chien-Kuo North Road
Taichung, Taiwan
E-mail: obs@csh.org.tw
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HORMONE THERAPY AND CARDIOVASCULAR DISEASE
Reply:
Dear Dr Tsai Horng-Jyh,
Thank you for your comments on the review article
“Hormone therapy and cardiovascular disease”. I com-
pletely agree with your opinion that RCTs are now con-
sidered as the “gold standard” in the area of clinical
research. Therefore, the WHI as an RCT study had a
tremendous impact on both the public and the clini-
cians. Although these RCTs have contributed to our
understanding of the benefit:risk relation associated
with HT, they have not answered questions regarding the
effect of such a therapy on cardiovascular risk. As per
your comments, as an example of evidence-based medi-
cine, their results do deserve consideration. However,
if we are to adhere to the principles of evidence-based
medicine, these results cannot be extrapolated to a
different population from the one studied in the trial,
not to a different HT regimen. Thus, as per your com-
ments “…in clinical trials, the investigators manipulate
the administration of a new intervention and measure
the effect of that manipulation, whereas observational
studies only observe associations (correlations) between
the treatments experienced by participants and their
health status or disease”, RCTs may reveal the effects
from only one kind of regimen in HT, as well as the
effects in advanced-age population. The significance
of observational trials (you may prefer observational
studies) is that they did not restrict to one type of HT
and they evaluated a younger population. That is why I
have to mention the difference between observational
and RCT studies. Therefore, serious questions remain
regarding the choice of HT preparations, different
estrogen and progestin combinations and doses, and
more importantly, the age and physical conditions, at
which women are exposed to these agents.
Epidemiologic approaches used to study the asso-
ciation between HT and cardiovascular risk include
case-control, cross-sectional, prospective, and cohort
with internal controls studies. Most cited observa-
tional papers in this manuscript are from prospective
observational studies. Thus, they actually involve some
kind of trials (HT). The description “observational tri-
als of HT” has also been noted in many international
papers and presentations. However, using “obser-
vational study” may be better than “observational 
trials”.
Thank you for your correction. The reference num-
bers quoted in both Tables 1 and 2 are incorrect, but
they were correct in the manuscript. I have amended
them above.
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Table 1. Summary of randomized clinical trials of hormone therapy by evaluating intermediate coronary artery disease 
outcomes
Study Age of subjects, yr Regimens Effect
ERA [42] 65.8 CEE/CEE + MPA ↔
PHOREA [43] 17β-E2 + gestodene ↔
EPAT [44] 62.2 17β-E2 +
HERS B-Mode substudy [45] 67 CEE + MPA ↔
WAVE [46] 65 CEE/CEE + MPA ↔
WELL-HART [47] 63.5 17β-E2/17β-E2 + MPA ↔
CEE = conjugated equine estrogen; MPA = medroxyprogesterone acetate; 17b-E2 = 17b-estradiol.
Table 2. Summary of randomized clinical trials of hormone therapy on cardiovascular disease outcomes
Age, yr Regimen Effect Early events
Primary prevention studies
WHI [11] 63.3 CEE + MPA ↑ ↑
WHI update [13] 63.3 CEE + MPA ↔ ↑
WHI [12] 63.6 CEE ↔ ↔
Secondary prevention studies ↑
HERS [14,48] 66.7 CEE + MPA ↔
PHASE [49] 66.5 Transdermal E2 + NETA ↔
ESPRIT [50] 62.6 E2 ↔
WHISP [51] > 55 17β-E2 + NETA ? ↔
CEE = conjugated equine estrogen; MPA = medroxyprogesterone acetate; E2 = estradiol; NETA = norethisterone acetate.
